JMC14 是一种具有选择性且口服有效的 PI3Kδ/CSF1R 抑制剂,对 PI3Kδ 和 CSF1R 的 IC50 分别为 12 nM 和 143 nM,能够优先抑制 PI3Kδ 介导的细胞层面信号传导,并在体内外均表现出对 B 细胞淋巴瘤和三阴性乳腺癌 (TNBC) 强大的抗肿瘤活性,可用于抗肿瘤免疫的研究。
产品编号: MS-D85495 CAS No.: 2256080-83-6 分子式: C26H34F3N7O2 分子量: 533.59
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

JMC14 是一种具有选择性且口服有效的 PI3Kδ/CSF1R 抑制剂,对 PI3Kδ 和 CSF1R 的 IC50 分别为 12 nM 和 143 nM,能够优先抑制 PI3Kδ 介导的细胞层面信号传导,并在体内外均表现出对 B 细胞淋巴瘤和三阴性乳腺癌 (TNBC) 强大的抗肿瘤活性,可用于抗肿瘤免疫的研究。

生物实验数据

生物活性 JMC14 is a selective and orally active PI3Kδ/CSF1R inhibitor with IC50 values of 12 nM and 143 nM for PI3Kδ and CSF1R, respectively, which preferentially inhibits PI3Kδ-mediated cellular signaling and exhibits potent antitumor activity against B-cell lymphoma and triple-negative breast cancer (TNBC) both in vitro and in vivo, and can be used for research on antitumor immunity.
IC50 & Target

PI3Kα

389 nM (IC50)

PI3Kβ

890 nM (IC50)

PI3Kγ

>10000 nM (IC50)

体外研究
(In Vitro)

JMC 14 (0-10 μM, 1 h) 通过阻断 PI3K 介导的信号传导抑制 DLBCL 细胞增殖。
JMC14 (0.01-10 μM,72 h) 通过破坏 CSF1/CSF1R 信号轴及其下游通路,在 M-NFS-60 细胞中发挥强大的抗增殖活性。
JMC14 (0.01-10 μM,72 h) 可抑制三阴性乳腺癌细胞的增殖。

Cell Proliferation Assay

Cell Line: M-NFS-60 myeloid leukemia cells
Concentration: 0.01, 0.1, 1, 10 μM
Incubation Time: 72 h
Result: Concentration-dependently inhibited the proliferation stimulated by CSF-1.
Had inhibitory potency on M-NFS-60 cell proliferation with IC50 values of 289 nM and 221 nM, respectively.

Cell Proliferation Assay

Cell Line: TNBC 4T1, PY8119 and EMT6
Concentration: 0.1, 1, 10 μM
Incubation Time: 72 h
Result: Demonstrated moderate antiproliferative activity against all three cell lines, with IC50 values of 7.9 μM, 5.5 μM, or 6.5 μM, respectively.

Western Blot Analysis

Cell Line: ABC-DLBCL TMD8 cells, GCB-DLBCL SU-DHL-6 and Pfeiffer cells
Concentration: 1 μM, 10 μM
Incubation Time: 1 h
Result: Suppressed AKT phosphorylation at S473 and T308 in a concentration-dependent manner.
Reduced AKT phosphorylation levels by approximately 40%.
Effectively inhibited the phosphorylation of downstream targets such as p70S6K1, 4E-BP1, and S6 at 1 μM.
Reduced AKT phosphorylation at S473 by 44.7%, while phosphorylation of p70S6K1 at T389 and S6 at S240/242 or S235/236 decreased by 39.7%, 55.4% or 50.6%, respectively at 10 μM.

Western Blot Analysis

Cell Line: TMD8, SU-DHL-6, Pfeiffer
Concentration: 0, 0.01, 0.03, 0.1, 0.3, 1.0 μM
Incubation Time: 1 h
Result: Suppressed AKT phosphorylation at S473 and T308 in a concentration-dependent manner across all analyzed DLBCL cell lines.
Inhibited AKT phosphorylation by approximately 40% at 1 μM or 10 μM in TMD8 and Pfeiffer cells.

Western Blot Analysis

Cell Line: TNBC 4T1, PY8119 and EMT6
Concentration: 0, 0.1, 0.3, 1, 10 μM
Incubation Time: 1 h
Result: Inhibited the phosphorylation of AKT, S6K, and S6, key signaling components downstream of PI3K, in a concentration-dependent manner.
was required to achieve similar levels to inhibit the phosphorylation of S6K and S6 compared to that of AKT with lower concentration.
Exerted lower potency in inhibiting Erk1/2 phosphorylation, achieving only 20% inhibition at a concentration of 10 μM.
体内研究
(In Vivo)

JMC14 (10-100 mg/kg,口服,每日一次,持续 21 天) 能够抑制 TMD8 肿瘤异种移植模型以及 DLBCL PDX 的肿瘤生长。
JMC14 (100 mg/kg,口服,每日一次,持续 13 天) 在 M-NFS-60 髓系白血病模型中通过阻断 CSF1R 和 PI3K 信号通路显示出强效的活性。
JMC14 (25-100 mg/kg,口服,每日一次,持续 18 天) 能够抑制 PY8119 同种异体移植瘤的生长,并重塑肿瘤微环境。

Animal Model: TMD8 xenograft model (B-cell lymphoma), female Balb/c SCID mice
Dosage: 10 mg/kg, 30 mg/kg, 100 mg/kg
Administration: Oral gavage (p.o.), once daily for 21 days
Result: Resulted in a dose-dependent inhibition of tumor growth.
Significantly inhibited the growth of xenografts with a T/C value of 17.6%.
Reduced significantly phosphorylated AKT at S473 1 h after administration at both 30 and 100 mg/kg.
Recovered phosphorylated AKT 8 h after treatment at 30 mg/kg, while inhibition of AKT phosphorylation persisted up to 8 h and was reversed up to 24 h upon treatment.
Significantly suppressed the growth of LY-24-0063 PDX, resulting in a T/C value of 35.2% at 100 mg/kg.
Exhibited marginal effect, with T/C values of 94.0% or 82.5%, respectively at 10 mg/kg or 30 mg/kg.
Animal Model: SCID mice bearing M-NFS-60 xenografts model
Dosage: 100 mg/kg
Administration: Oral gavage (p.o.), once daily for 13 days
Result: Significantly suppressed tumor growth, yielding a T/C value of 25.4% at 100 mg/kg.
Observed no significant changes in body weight between treatment and control groups.
Decreased the anti-tumor effect correlated with the suppression of CSF1R and PI3K signaling pathways in the phosphorylation of CSF1R, Erk1/2, AKT, S6K and S6 in tumor tissues collected 2 h after a single dose.
Animal Model: Immune-competent model induced in PY8119 cells established in C57BL/6 mice
Dosage: 25, 50, 100 mg/kg
Administration: Oral gavage (p.o.)., once daily for 18 days
Result: Inhibited the tumor growth in a dose-dependent manner.
Exhibited pronounced tumor growth inhibition with a T/C value of 26.9% at 100mg/kg.
Animal Model: Immune-competent model, PY8119 cells were orthotopically inoculated into C57BL/6 mice
Dosage: 100 mg/kg
Administration: Oral gavage (p.o.), single dose, tumor tissues were collected at 2, 4, and 8 h after treatment.
Result: Effectively downregulated the phosphorylation of CSF1R, AKT, S6K, and S6 within 2 h after administration, while a longer time was needed to suppress the Erk1/2 phosphorylation.
Recovered phosphorylation of AKT and S6 partially 8 h post-treatment.
Increased the staining CD45 markedly after treatment, indicating enhanced immune cell infiltration.
Decreased the F4/80 staining, the staining of CD206 representing immunosuppressive M2 macrophages significantly particularly.

化学信息

产品应用

1. 该化合物可作为示踪剂。

2. 该化合物可作为 NMR、GC-MS 或 LC-MS 分析中的内标品,用于定量分析。

分子量 533.59
分子式 C26H34F3N7O2
CAS No. 2256080-83-6

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础